For many years, Professor Chao-Neng Wang has been committed to the systematic application of AI technology in cancer genomics, establishing a comprehensive research framework covering cancer gene screening processes and immunotherapy assessment. He has further extended AI methodologies into the field of drug design and development, integrating cancer genomic information with immunotherapy techniques to lay a critical foundation for next-generation precision medicine.
In terms of clinical smart healthcare applications, Professor Chao-Neng Wang has collaborated with medical teams across various specialties, including pediatrics, nephrology, cardiology, and emergency medicine, to develop AI-core medical decision support systems. These systems assist clinicians in obtaining more real-time and reliable data support for disease diagnosis and treatment planning. His research achievements have also received national recognition: in 2024, he won the National Innovation Award for the "Intelligent Monitoring and Early Warning System for Home Hemodialysis," and in 2025, he received the award again for the "AI-Assisted Detection of Peritoneal Dialysis Catheter Exit Site Infection and Remote Monitoring Cloud Platform," demonstrating continuously deepening technical capabilities.
Regarding regulatory and industrial layout, Professor Chao-Neng Wang has actively assisted Asia University in promoting the research, development, and commercialization of Software as a Medical Device (SaMD). The university has obtained medical device manufacturer and seller licenses, completing a key milestone in Asia University's transition from smart healthcare R&D to industrialization, setting an example for academic research institutions entering the digital health industry.
Beyond precision medicine, Professor Chao-Neng Wang is also actively involved in corporate digital transformation practices, applying AI technology to help several listed companies build intelligent processes, fully embodying the value of an innovative ecosystem driven by the synergy of industry, academia, and research.
Professor Chao-Neng Wang was awarded the 2026 AI AWARD Best Solution Academic-Industry Award. The judging committee recognized his outstanding contributions in advancing both academic research and industrial application. From cancer gene screening and immunotherapy integration to computational drug design, he has constructed a complete AI-driven precision medicine research chain. On the industrial translation front, he has successively won the National Innovation Award, promoted the commercialization of SaMD, and assisted multiple listed companies in implementing AI applications, fully demonstrating his ability to transform cutting-edge technology into tangible social and industrial benefits. Professor Chao-Neng Wang's cross-disciplinary research vision and spirit of industry-academia co-creation embody the core essence of this award, making him a truly deserving recipient.
